The percentage on each card is IAM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● GlobeNewsWireNov 16, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Launched Enchant® v3, a 41-billion-parameter transformer model for drug discovery and development, to drive decisions across our internal and partnership activities Signed AI discovery collaborations with Bayer and AbbVi…
● GlobeNewsWireNov 9, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Iambic to participate in Jefferies Global Healthcare Conference
Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026 Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026…
● Business WireOct 26, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinica…
U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research is expected to for o…
● Business WireOct 14, 2026 · 18:52 ETCOMPANY'S OWN WORDS
Iambic Announces Pricing of Initial Public Offering
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of i…
Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
Iambic Therapeutics, which is backed by Nvidia , is aiming to raise as much as $159.4 million in its US IPO, a regulatory filing showed on Thursday, as biotech companies remain a bright spot in an otherwise subdued IPO…
Article counts from the last market-wide feed page, across every symbol we track and not just IAM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.